Skip to main content

Table 4 Univariate and Multivariate results for overall survival (Discovery cohort)

From: Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer

A. Case–control approach
Parameter Univariate analysis Multivariate analysis
HR (95 % CI) p-value HR (95 % CI) p-value
Risk score 2.44 (1.28 – 4.68) 0.01 2.71 (1.38 – 5.35) 0.004
Tumor stage 0.42 (0.22 – 0.81) 0.01 0.36 (0.18 – 0.74) 0.01
Tumor grade 1.93 (0.99 – 3.75) 0.05   
Age at diagnosis 1.05 (1.02 – 1.09) 0.003 1.04 (1.01 – 1.07) 0.02
TNBC status 0.88 (0.43 – 1.77) 0.71   
B. Case-only approach
Parameter Univariate analysis Multivariate analysis
HR (95 % CI) p-value HR (95 % CI) p-value
Risk score 2.48 (1.34 – 4.61) 0.004 2.76 (1.47 – 5.19) 0.002
Tumor stage 0.42 (0.22 – 0.81) 0.01 0.37 (0.19 – 0.72) 0.004
Tumor grade 1.93 (0.995 – 3.75) 0.05   
Age at diagnosis 1.05 (1.02 – 1.09) 0.003   
TNBC status 0.88 (0.43 – 1.77) 0.71   
  1. A and B: The four and 11 miRNAs from Table 1A and B respectively were used to construct risk scores. Receiver Operating Characteristics Curve was used to dichotomize cases into low and high-risk groups. Univariate Cox proportional hazards regression model was run for risk score and for other clinical parameters. In the multivariate analysis, risk score was significant with p < 0.05 after adjusting for confounders.
  2. HR Hazard Ratio; CI Confidence Interval; TNBC Triple Negative Breast Cancer